MGP
JAZZ icon

Metis Global Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Metis Global Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,225
Closed -$268K – 774
2024
Q1 		$268K Buy
2,225
+22
+1% +$2.69K 0.01% 673
2023
Q4 		$271K Sell
2,203
-70
-3% -$8.73K 0.01% 657
2023
Q3 		$294K Buy
2,273
+51
+2% +$6.8K 0.01% 629
2023
Q2 		$275K Buy
2,222
+372
+20% +$50.1K 0.01% 637
2023
Q1 		$271K Buy
+1,850
New +$274K 0.02% 600

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
PCM
Polaris Capital Management Boston, Massachusetts $1.22B AUM 26.01% 1-Year Est. Return

Metis Global Partners's JAZZ Position: Q2 2024 in Review

Metis Global Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2024, closing a stake of 2,225 shares — an estimated $268K sold.

Metis Global Partners first reported a position in JAZZ in Q1 2023 and held it in 5 quarters. The position peaked at $294K in Q3 2023. 455 funds tracked by Wall St. Rank hold JAZZ as of Q2 2024.

  • Metis Global Partners reported no remaining Jazz Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Metis Global Partners sold 2,225 Jazz Pharmaceuticals shares in Q2 2024, an estimated $268K.
  • Metis Global Partners first reported a position in Jazz Pharmaceuticals in Q1 2023 and held it in 5 quarters.
  • Metis Global Partners's Jazz Pharmaceuticals position peaked at $294K in Q3 2023.
  • 455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2024.

Based on Metis Global Partners's 13F filing for Q2 2024, filed 6 Aug 2024.